Does human pancreatic adenocarcinoma contain a side population resistant to gemcitabine?
We identified a SP in human PDAC and uncovered a chemoresistant and CSC-associated phenotype. This SP may represent a new therapeutic target in pancreatic cancer.
Vaccine group agglutinin value comparisons strongly depend on assay antigens used.